Vol. 3 No. 6 (2023)
Reimbursement Recommendations

Atogepant (Qulipta)

Published June 29, 2023

Key Messages

  • CADTH recommends that Qulipta be reimbursed by public drug plans for the prevention of episodic migraine, if certain conditions are met.
  • Qulipta should only be reimbursed for adults with episodic migraine, according to the criteria used by public drug plans for other calcitonin gene-related peptide (CGRP) inhibitors for the prevention of episodic migraine.
  • In addition to following the pre-existing criteria for other CGRP inhibitors, Qulipta should not be used in combination with other CGRP inhibitors. Qulipta should only be reimbursed if the cost is reduced such that the total treatment cost of Qulipta does not exceed the total treatment cost of the least costly CGRP inhibitor reimbursed for the preventive treatment of episodic migraine in adults.